Bradley McGregor, MD, Dana-Farber Cancer Institute, and Christopher Wallis, MD, PhD, FRCSC, University of Toronto, continue their discussion by pivoting to the BLASST-1 trial, which evaluated the ability of an AI model to identify non-responders to neoadjuvant chemo-immunotherapy based on computerized image features of nuclear morphology and architecture on pre-treatment TURBT tissues.
BLASST-1: AI Prognostic Model in MIBC for Neoadjuvant IO, Chemo
By Brad McGregor, MD, Christopher Wallis, MD, PhD, FRCSC - Last Updated: January 26, 2024Related Posts
Dr. Calais explains the utility of PSMA PET prior to RT for unfavorable intermediate-risk or high-risk prostate cancer.
Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data.
Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC.
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.